Search results for #IgAN
Evidence from the large VALIGA cohort validates the subclassification of focal segmental glomerulosclerosis in #IgA #nephropathy doi.org/10.1016/j.kint… @queensu @UMontreal Oxford University Hospitals NHS Foundation Trust #IgAN #FSGS
A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of #atacicept for treatment of #IgA #nephropathy doi.org/10.1016/j.kint… @StanfordDeptMed @UBCDoM @georgeinstitute @UniklinikAachen @Sydney_Uni @uniofleicester #OpenAccess #IgAN #glomerulardisease
Save the date-spread the word. May 10th, 1800 - Interesting #debates lined up. #IgAN #ANCAVASCULITIS #C3GN #glomerulardisease @isn_india @ISGDtweets
Save the date-spread the word. May 10th, 1800 - Interesting #debates lined up. #IgAN #ANCAVASCULITIS #C3GN #glomerulardisease @isn_india @ISGDtweets
Findings from a recent study highlight the potential value of the light microscopy pattern of glomerular injury and the intensity of mesangial C3 deposition for stratifying #renal outcomes in #IgAN. hcplive.com/view/study-sug…
Learn about the four-hit hypothesis and the role APRIL in IgA Nephropathy in our upcoming webinar. Register today! go.nephu.org/MK4m #IgAN #RareDisease #KidneyHealth #NephU #FourHitHypothesis
Our partner, Everest Medicines, has announced that the Hong Kong Department of Health has approved our treatment for adults with primary IgA nephropathy, expanding access to treatment for #IgAN across Asian territories. Read more: bit.ly/4b02TZQ
In “Recognizing & Addressing Symptom Burden For Patients With IgAN,” a recent NephU article, experts recognize just how influential IgAN is on a patient’s quality of life. Learn more by reading on NephU today! go.nephu.org/MLJX #RareDisease #IgAN #SymptomBurden
Everest Medicines Announces Hong Kong Department of Health Approval of Nefecon for the Treatment for Primary IgA Nephropathy in Adult Patients #ImmunoglobulinANephropathy, #IgAN, #IgANephropathy crweworld.com/article/news-p…
The unmet need of patients with IgA nephropathy has been long underscored by a lack of disease-specific treatment options. With our FDA-approved treatment, patients are now exposed to new possibilities. Watch Chief Medical Officer, Richard Philipson, discuss the #IgAN landscape.
Tune into this webinar to receive a detailed overview of the Four-Hit Hypothesis as well as explain the role of APRIL in disease pathogenesis. Register today! go.nephu.org/MGhf #igan #nephrology #kidneydisease #fourhithypothesis
Want to catch up on the latest in IgAN care? Check out this upcoming LIVE event to hear experts discuss innovations in treatment. Don’t miss out on this comprehensive look at the IgAN therapeutic landscape: ow.ly/a9Xb50Rr18q #MedicalEducation #CME #IgAN #Nephrology
Thank you @ISGDtweets & @isn_india for the invitation to kick off this exciting event & speak about recent clinical trials and new drugs to treat #IgAN Looking forward to a lively discussion!
Thank you @ISGDtweets & @isn_india for the invitation to kick off this exciting event & speak about recent clinical trials and new drugs to treat #IgAN Looking forward to a lively discussion!
Hot Topics in Glomerulnephritis. An online symposium organized by the @isn_india and @ISGDtweets. Session 1 on #IgAN with @SWadhwaniMD @kdjhaveri and @Suceena Register here 👉 us06web.zoom.us/webinar/regist…
Serum Gd-IgA1 was not associated with validated prognostic risk factors but was negatively correlated with kidney function, suggesting further research could detail its utility as a biomarker for risk of #IgAN progression. hcplive.com/view/study-hig…
Did you know the highest prevalence of IgAN is seen in individuals of East Asian descent? Learn more from our infographic, “Kidney Disease In Asian American & Pacific Islanders.” Download now! go.nephu.org/MCqg #IgAN #kidneyhealth #asianamericankidneyhealth #NephU #CKD
Yesterday, @Calliditas1 announced positive results from the NefIgArd open-label extension study of Nefecon in patients with primary #IgAN on optimized RASi therapy. Read more: hcplive.com/view/callidita…
Calliditas Announces Positive NefIgArd Open Label Extension Results in Primary IgA Nephropathy (IgAN) - check the link for more info ow.ly/Jo1450Rnl4i @Calliditas1 # IgANephropathy #IgAN #RareDiseases
Today we announced with CSL Vifor that the European Commission has approved FILSPARI (sparsentan) for the treatment of IgA nephropathy (#IgAN). #InRareForLife Press release: bit.ly/3w9cfUc